Cypherpunk Technologies Inc. (CYPH)
NASDAQ: CYPH · Real-Time Price · USD
1.110
-0.160 (-12.60%)
At close: Dec 5, 2025, 4:00 PM EST
1.160
+0.050 (4.50%)
After-hours: Dec 5, 2025, 7:57 PM EST
Cypherpunk Technologies Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
52
Market Cap
62.88M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Berkshire Hathaway | 372.13B |
| JPMorgan Chase & Co. | 167.23B |
| Bank of America | 101.45B |
| Wells Fargo & Company | 79.07B |
| Morgan Stanley | 68.53B |
| American Express Company | 65.29B |
| HSBC Holdings | 57.98B |
| The Goldman Sachs Group | 57.34B |
CYPH News
- 24 days ago - Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results - PRNewsWire
- 24 days ago - Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy - PRNewsWire
- 6 weeks ago - Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025 - PRNewsWire
- 2 months ago - Leap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy - PRNewsWire
- 2 months ago - Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy - PRNewsWire
- 2 months ago - Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025 - PRNewsWire
- 4 months ago - Leap Therapeutics Reports Second Quarter 2025 Financial Results - PRNewsWire
- 5 months ago - Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives - PRNewsWire